Journal
JOURNAL OF NEUROIMAGING
Volume 24, Issue 3, Pages 266-272Publisher
WILEY
DOI: 10.1111/jon.12006
Keywords
Brain FDG metabolism; anticancer therapy; pharyngeal cancer
Funding
- Taiwan Department of Health Clinical Trial and Research Center and for Excellence [DOH101-TD-B-111-004]
- Taiwan Department of Health Cancer Research Center for Excellence [DOH101-TD-C-111-005]
- International Research-Intensive Centers of Excellence in Taiwan (I-RiCE) [NSC101-2911-I-002-303]
- [DMR-101-060]
- [DMR-101-061]
Ask authors/readers for more resources
BACKGROUNDThe current study aimed to evaluate whether therapy-related changes occurred in brain metabolism at an earlier stage during the course of anticancer therapy. METHODSWe recruited 14 non-diabetic male patients with newly diagnosed pharyngeal squamous cell carcinoma. We analyzed the patients' serial brain FDG PET/CT scans by SPM8 to establish whether any therapy-related changes had occurred in brain FDG metabolism, either during or after the course of therapy. RESULTSDecreased metabolism was noted during the anticancer therapy, displaying a symmetric pattern involving bilateral basal ganglia and bilateral occipital lobes. The decrease in FDG metabolism in these regions persisted after the anticancer therapy had terminated. However, relative recovery of the metabolism was noted in the bilateral occipital lobes, whereas further deterioration was noted in bilateral basal ganglia. CONCLUSIONSThe current study revealed that unappreciable changes in brain metabolism can occur during the early course of anticancer therapy, and persist even after therapy has terminated. Although the exact mechanism remains unclear, these changes may be related to the systemic effects of chemotherapy or radiotherapy as well as subclinical cancer-related depressive or adjustment mood disorder.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available